ORCID Profile
0000-0002-8567-6725
Current Organisations
Karolinska Institutet
,
Healthcare Provision, Stockholm County
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: American Association for Cancer Research (AACR)
Date: 12-2006
DOI: 10.1158/1055-9965.EPI-06-0489
Abstract: The effect of classic breast cancer risk factors on hormone receptor-defined breast cancer is not fully clarified. We explored these associations in a Swedish population-based study. Postmenopausal women ages 50 to 74 years, diagnosed with invasive breast cancer during 1993 to 1995, were compared with 3,065 age frequency-matched controls. We identified 332 estrogen receptor (ER−) and progesterone receptor (PR−) negative, 286 ER+PR−, 71 ER−PR+, 1,165 ER+PR+, and 789 tumors with unknown receptor status. Unconditional logistic regression was used to calculate odds ratios (OR) and 95% confidence intervals (95% CI). Women ages ≥30 years, compared with those ages 20 to 24 years at first birth, were at an increased risk of ER+PR+ tumors (OR, 1.5 95% CI, 1.2-1.8) but not ER−PR− tumors (OR, 1.1 95% CI, 0.8-1.6). Women who gained ≥30 kg in weight during adulthood had an ∼3-fold increased relative risk of ER+PR+ tumors (OR, 2.7 95% CI, 1.9-3.8), but no risk increase of ER−PR− tumors (OR, 1.0 95% CI, 0.5-2.1), compared with women who gained & kg. Compared with never users, women who used menopausal estrogen-progestin therapy for at least 5 years were at increased risk of ER+PR+ tumors (OR, 3.0 95% CI, 2.1-4.1) but not ER−PR− tumors (OR, 1.3 95% CI, 0.7-2.5). In conclusion, other risk factors were similarly related to breast cancer regardless of receptor status, but high age at first birth, substantial weight gain in adult age, and use of menopausal estrogen-progestin therapy were more strongly related to receptor-positive breast cancer than receptor-negative breast cancer. (Cancer Epidemiol Biomarkers Prev 2006 (12):2482–8)
Publisher: Public Library of Science (PLoS)
Date: 03-04-2012
Publisher: Oxford University Press (OUP)
Date: 15-08-2002
DOI: 10.1093/AJE/KWF048
Abstract: This case-control study evaluated reproductive and other factors in relation to epithelial ovarian cancer (EOC) risk. Between 1993 and 1995, the authors recruited 655 EOC cases and 3,899 population controls aged 50-74 years who were born in and residents of Sweden. Data were collected through mailed questionnaires. Odds ratios were estimated by unconditional logistic regression. Parity reduced EOC risk (odds ratio = 0.61, 95% confidence interval (CI): 0.46, 0.81) for uniparous compared with nulliparous women. The risk of EOC decreased with incomplete pregnancies, early menopausal age, late age at first birth, and unilateral oophorectomy increased with family history of ovarian cancer and was not associated with menarcheal age, lactation, irregular menses, and menopausal symptoms. Histology-specific odds ratios of EOC for ever compared with never users of oral contraceptives were: serous, 0.56 (95% CI: 0.42, 0.74) mucinous, 1.96 (95% CI: 1.04, 3.68) endometrioid, 0.71 (95% CI: 0.49, 1.03) clear cell, 0.66 (95% CI: 0.31, 1.43) and all EOCs, 0.73 (95% CI: 0.59, 0.90). Prolonged oral contraceptive use reduced EOC risk, with persistent protection up to 25 years after the last use. Ever use of hormone replacement therapy increased EOC risk (odds ratio = 1.41, 95% CI: 1.15, 1.72). Among etiologic hypotheses, the retrograde transportation hypothesis accommodates most epidemiologic findings concerning EOC risk.
Publisher: Elsevier BV
Date: 11-2012
Publisher: Elsevier BV
Date: 12-2001
Publisher: Springer Science and Business Media LLC
Date: 11-2002
Publisher: Springer Science and Business Media LLC
Date: 02-2006
DOI: 10.1186/BCR1378
No related grants have been discovered for Cecilia Magnusson.